WEBULL
News
INKT
10.28
-6.12%
-0.67
Mink Therapeutics Director Barbara Ryan Disposes of Common Shares
Reuters · 3d ago
Weekly Report: what happened at INKT last week (0223-0227)?
Weekly Report · 5d ago
Weekly Report: what happened at INKT last week (0216-0220)?
Weekly Report · 02/23 09:37
Weekly Report: what happened at INKT last week (0209-0213)?
Weekly Report · 02/16 09:37
Weekly Report: what happened at INKT last week (0202-0206)?
Weekly Report · 02/09 09:39
MiNK Therapeutics announces new invariant natural killer T cells data
TipRanks · 02/04 10:25
Reported Earlier, MiNK Therapeutics Highlights Depletion Of iNKT Cells In Advanced IPF At Keystone Symposia, Showcasing Potential For Disease-Modifying Therapy
Benzinga · 02/04 08:42
MiNK Therapeutics Unveils New Data Supporting iNKT Cell Therapy for Idiopathic Pulmonary Fibrosis
Reuters · 02/04 02:31
Mink Therapeutics präsentiert neue Daten zu iNKT-Zelltherapie bei idiopathischer Lungenfibrose
Reuters · 02/04 02:30
MiNK Therapeutics Unveils Data Supporting iNKT Cell Therapy for Advanced Idiopathic Pulmonary Fibrosis
Reuters · 02/04 02:30
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
Barchart · 02/03 20:30
Weekly Report: what happened at INKT last week (0126-0130)?
Weekly Report · 02/02 09:38
Weekly Report: what happened at INKT last week (0119-0123)?
Weekly Report · 01/26 09:38
Weekly Report: what happened at INKT last week (0112-0116)?
Weekly Report · 01/19 09:42
Weekly Report: what happened at INKT last week (0105-0109)?
Weekly Report · 01/12 09:40
MiNK, University of Wisconsin-Madison announce Phase 1 agenT-797 trial
TipRanks · 01/08 17:10
MiNK Therapeutics Plans To Initiate Phase 1 Clinical Study To Evaluate Safety, Tolerability Of AgenT-797 To Treat Graft-Versus-Host Disease, Relapse, Other Post-Transplant Complications In Patients With High-Risk Leukemias
Benzinga · 01/08 17:06
MiNK Therapeutics Wins Grants to Advance Phase 1 Trial of Allo-iNKT Cell Therapy for GvHD Prevention
Reuters · 01/08 17:00
MINK THERAPEUTICS AND UNIVERSITY OF WISCONSIN–MADISON ANNOUNCE PHASE 1 CLINICAL TRIAL OF ALLO-INKT CELL THERAPY (AGENT-797) TO EVALUATE PREVENTION OF GRAFT-VERSUS-HOST DISEASE
Reuters · 01/08 17:00
Weekly Report: what happened at INKT last week (1229-0102)?
Weekly Report · 01/05 09:38
More
Webull provides a variety of real-time INKT stock news. You can receive the latest news about Mink Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.